Kypha Revenue and Competitors
Estimated Revenue & Valuation
- Kypha's estimated annual revenue is currently $8M per year.
- Kypha's estimated revenue per employee is $251,000
Employee Data
- Kypha has 32 Employees.
- Kypha grew their employee count by -3% last year.
Kypha's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
Kypha Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Kypha?
Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing. RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications. Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
keywords:N/A
N/A
Total Funding
32
Number of Employees
$8M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Dublin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 32 | 33% | N/A |
#2 | $3.7M | 32 | -64% | N/A |
#3 | $3.1M | 32 | 39% | N/A |
#4 | N/A | 32 | 45% | N/A |
#5 | $5.4M | 32 | 60% | N/A |